In biotech, the right connection can lead to roles that never reach public listings. From targeted event participation to authentic online engagement, networking is about creating trust that leads to ...

What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts ...

This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen ...

Biotech has never been for the faint of heart. It’s a roll-of-the-dice proposition in which companies spend upward of a ...

Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

Legend Biotech ( LEGN +18.42%) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...

If biotech funding continues to increase this year, Danaher could benefit.

Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...

A Woburn biotechnology company laid off more than 200 Massachusetts employees last week, and state filings warn more cuts may ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

Garabedian joins Bloomberg Intelligence analyst Sam Fazeli to explain why he left the public-company operator track to back biotech earlier, where better decisions can create the biggest value ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...